Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.

Blood
Jianxiang WangXiao-Jun Huang

Abstract

Treatment with a tyrosine kinase inhibitor (TKI) targeting BCR-ABL1 is currently the standard of care for patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP). In this study, we present results of the ENESTchina (Evaluating Nilotinib Efficacy and Safety in Clinical Trials-China) that was conducted to investigate nilotinib 300 mg twice daily vs imatinib 400 mg once daily in a Chinese population. ENESTchina met its primary end point with a statistically significant higher rate of major molecular response (MMR; BCR-ABL1 ≤0.1% on the International Scale) at 12 months in the nilotinib arm vs the imatinib arm (52.2% vs 27.8%; P < .0001), and MMR rates remained higher with nilotinib vs imatinib throughout the follow-up period. Rates of complete cytogenetic response (0% Philadelphia chromosome-positive [Ph+] metaphases by standard cytogenetics) were comparable and ≥80% by 24 months in both arms. The estimated rate of freedom from progression to accelerated phase/blast crisis at 24 months was 95.4% in each arm. The safety profiles of both drugs were similar to those from previous studies. In conclusion, rates of MMR at 12 months were superior with nilotinib vs imatinib in Chinese patients with newly diagnosed Ph+ CML-C...Continue Reading

References

Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Apr 2, 2004·Toxicological Sciences : an Official Journal of the Society of Toxicology·Harvey J ClewellJustin G Teeguarden
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele BaccaraniUNKNOWN European LeukemiaNet
Jun 8, 2010·The New England Journal of Medicine·Giuseppe SaglioUNKNOWN ENESTnd Investigators
Apr 24, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerUNKNOWN AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis
Nov 14, 2013·Journal of the American Pharmacists Association : JAPhA
Dec 4, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rüdiger HehlmannAndreas Hochhaus
Dec 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philippe RousselotFrançois-Xavier Mahon

❮ Previous
Next ❯

Citations

Jan 23, 2016·American Journal of Hematology·Elias Jabbour, Hagop Kantarjian
Nov 15, 2015·Science China. Life Sciences·Meng Lv, XiaoJun Huang
Nov 21, 2015·Blood·Richard A Larson
Mar 15, 2016·American Journal of Hematology·Gabriele GugliottaUNKNOWN GIMEMA CML Working Party
Dec 8, 2015·Hematology·Richard A Larson
Nov 3, 2016·Nature Reviews. Clinical Oncology·Gianantonio RostiMichele Baccarani
Oct 23, 2016·American Journal of Hematology·Fausto CastagnettiMichele Baccarani
Oct 4, 2017·Leukemia & Lymphoma·Giuseppe Saglio, Elias Jabbour
Jan 13, 2018·Clinical Pharmacology and Therapeutics·Gaurav BajajJennifer Sheng
Mar 26, 2019·British Journal of Clinical Pharmacology·Mariana M FachiRoberto Pontarolo
Apr 2, 2016·The Oncologist·Simona SoveriniGiovanni Martinelli
Jan 5, 2020·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Deepam Pushpam, Sameer Bakhshi
Apr 3, 2020·American Journal of Hematology·Elias Jabbour, Hagop Kantarjian
Feb 4, 2016·The Cancer Journal·Priyanka A Pophali, Mrinal M Patnaik
Jul 2, 2016·Cancer Medicine·Stéphanie Dulucq, Francois-Xavier Mahon
Dec 28, 2018·Blood Advances·Andrew Hantel, Richard A Larson
Feb 8, 2018·American Journal of Hematology·Elias Jabbour, Hagop Kantarjian
Nov 20, 2019·Leukemia & Lymphoma·Riad El FakihElias Jabbour
May 26, 2016·Asian Pacific Journal of Cancer Prevention : APJCP·Adisak TantiworawitLalita Norasetthada
Sep 25, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jae-Yong KwakDong-Wook Kim
Sep 16, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Li ZhangJianxiang Wang
Apr 15, 2020·Cancer Cell·Theodore P BraunBrian J Druker
Sep 28, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Mohammad Hossein YazdiMohammad Abdollahi
Feb 24, 2021·Expert Review of Clinical Pharmacology·Zeng WangPeihua Luo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.